Ceribell, Inc. (CBLL)
NASDAQ:CBLL
Want to see CBLL full AI Analyst Report?
CBLL Stock Chart & Stats
$18.36
-$0.15(-0.64%)
At close: 4:00 PM EST
$18.36
-$0.15(-0.64%)
Day’s Range― - ―
52-Week Range$10.85 - $24.33
Previous CloseN/A
Volume46.56K
Average Volume (3M)265.67K
Market Cap
$700.80M
Enterprise Value$676.91M
Total Cash (Recent Filing)$141.18M
Total Debt (Recent Filing)$22.12M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 11, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding37,942,700
10 Day Avg. Volume244,220
30 Day Avg. Volume265,666
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.16
Price to Sales (P/S)9.00
P/FCF Ratio-19.28
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue7.12
Enterprise Value/Gross Profit8.12
Enterprise Value/Ebitda-11.82
Forecast
1Y Price Target
$28.50Price Target Upside55.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$113.99M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsVery high and stable gross margins (~84%–88%) indicate strong unit economics and pricing power for Ceribell's headband and software model. Durable gross profit per sale supports investments in sales and R&D while giving a clear path to leverage fixed costs as volumes scale over the next 2–3 years.
Commercial Traction & Revenue MomentumSustained 25%–30% revenue growth and accelerating hospital adoption (record utilization and largest quarterly net adds) show durable market acceptance. Growing installed base plus subscription elements create recurring revenue, improving lifetime value and supporting scalable go-to-market economics over multiple years.
Liquidity, Low Leverage & Reimbursement CatalystA strong cash balance and low debt provide runway to fund commercialization and R&D initiatives without immediate refinancing. Coupled with a favorable proposed NTAP reimbursement ($2,171/patient) and a $3.5B TAM, this underpins durable investment capacity and improves long‑term revenue recoverability once reimbursement finalizes.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow (~-$49M TTM) signals ongoing funding needs. Over a multi‑quarter horizon this increases reliance on external capital or dilution risk unless operating losses narrow materially, constraining long‑term strategic flexibility and increasing financing vulnerability.
Deep Net LossesA deeply negative net margin (~-64% TTM) despite strong revenue growth shows profitability remains distant. Continued large losses erode equity and reduce return prospects for shareholders absent meaningful operating leverage or sustained margin improvement over the next several quarters.
Rising OpEx And Litigation Drag; Early-stage IndicationsRapidly rising operating expenses (sales, marketing, R&D) plus elevated IP litigation costs are compressing adjusted EBITDA and delaying breakeven. New clinical indications are strategically valuable but early-stage, implying limited near‑term revenue offset and longer horizon to recoup upfront commercialization investment.
Ceribell, Inc. News
CBLL FAQ
What was Ceribell, Inc.’s price range in the past 12 months?
Ceribell, Inc. lowest stock price was $10.85 and its highest was $24.33 in the past 12 months.
What is Ceribell, Inc.’s market cap?
Ceribell, Inc.’s market cap is $700.80M.
When is Ceribell, Inc.’s upcoming earnings report date?
Ceribell, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 56 days.
How were Ceribell, Inc.’s earnings last quarter?
Ceribell, Inc. released its earnings results on May 11, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.129.
Is Ceribell, Inc. overvalued?
According to Wall Street analysts Ceribell, Inc.’s price is currently Undervalued.
Does Ceribell, Inc. pay dividends?
Ceribell, Inc. does not currently pay dividends.
What is Ceribell, Inc.’s EPS estimate?
Ceribell, Inc.’s EPS estimate is -0.47.
How many shares outstanding does Ceribell, Inc. have?
Ceribell, Inc. has 37,942,700 shares outstanding.
What happened to Ceribell, Inc.’s price movement after its last earnings report?
Ceribell, Inc. reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went down -16.5%.
Which hedge fund is a major shareholder of Ceribell, Inc.?
Currently, no hedge funds are holding shares in CBLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ceribell, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.50 (55.23% Upside)
$28.50 (55.23% Upside)
Blogger Sentiment
Bullish
CBLL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 17.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $312.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.74%
12-Months-Change
Fundamentals
Return on Equity
-38.19%
Trailing 12-Months
Asset Growth
-16.58%
Trailing 12-Months
Company Description
Ceribell, Inc.
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
CBLL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and robust top-line growth (29% YoY revenue, record account additions, high 87% gross margin), alongside several strategic milestones (neonate/pediatric launches, delirium pilot with FDA clearance, favorable NTAP proposal, LVO Breakthrough designation) and a healthy cash position. Offsetting these positives are elevated operating expenses (+36% YoY), significant near-term litigation costs ($5.6M in Q1), a wider net loss ($19.7M), and continued adjusted EBITDA losses. Given the combination of accelerating revenue/market expansion and manageable but notable near-term expense pressures, the tone is constructive with near-term investment-driven profitability headwinds.View all CBLL earnings summariesCBLL Stock 12 Month Forecast
Average Price Target
$28.50
▲(55.23% Upside)
Technical Analysis
Ownership Overview
16.54% Insiders
22.80% Mutual Funds
33.68% Other Institutional Investors
19.76% Public Companies and
Individual Investors